Scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a finding that could help shape the next generation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.
🛡️
Just a quick checkWe’re checking your connection to prevent automated abuse
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Team finds way to reverse ovarian cancer’s chemo resistance | 5 | 8 | 25-06-2026 |
| 2 | Новое лекарство от агрессивных видов рака крови создают в Петербурге | 6 | 7 | 17-07-2026 |
| 3 | Chemotherapy leaves detectable DNA fingerprints in childhood tumors within 18 months | 0 | 8.21 | 23-07-2026 |
| 4 | A hidden weakness in deadly cancers could lead to powerful new treatments | 0 | 7.28 | 04-07-2026 |
| 5 | Common blood pressure drug could make cancer therapy far more powerful | 0 | 9.71 | 11-07-2026 |
| 6 | New, improved method to find and isolate the strongest cancer-fighting immune cells | 7 | 8 | 08-07-2026 |
| 7 | Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer | 0 | 10 | 28-07-2026 |
| 8 | Российские ученые создали препарат для снижения побочных эффектов при лечении рака | 5 | 7 | 05-07-2026 |
| 9 | Blood test finds hidden pancreatic cancer after treatment | 5 | 8 | 30-06-2026 |
| 10 | Family history raises breast cancer risk even when BRCA testing is negative | 0 | 9.88 | 30-07-2026 |